Gold's most recent position was Director of Global Aseptic Technology for
Pfizer Global Technology Services. After retiring from a 39-year career
in the pharmaceutical industry, Mr. Gold founded Pamigo Aseptic, a
consultancy focusing on aseptic pharmaceutical manufacturing.
"Paul brings extensive experience in aseptic processing operations to our
board of directors. He will help us accelerate the adoption of our
technologies for fill-finish and provide critical 'voice-of-customer'
guidance to maximize the value of our product roadmap. Paul shares
Vanrx's commitment to enabling more companies to efficiently and
consistently produce compliant sterile product for the patient," said
Chris Procyshyn, Chief Executive Officer of Vanrx Pharmasystems.
"I've been engaged with Vanrx technology since 2009. It has always seemed
to me that this is an innovative and practical way to improve sterility
assurance. It will be an honor to help guide the Vanrx team toward a
future where aseptic processing has been de-risked to the point where
terminal sterilization is no longer seen as the preferred way to ensure
delivering sterile product to the patient," said Paul Gold.
Among Mr. Gold's accomplishments is the co-invention of the Restricted
Access Barrier System (RABS), a method for aseptic process separation and
protection used globally in drug production facilities. His areas of
expertise include sterile suspension processing, formulation development,
equipment design, and product and process development for
aseptically-produced sterile products.
Gold holds a Master of Science (Synthetic Organic Chemistry) from the
University of Wisconsin, and a Bachelor of Science in chemistry from the
State University of New York at Albany. He is a member of the
International Society for Pharmaceutical Engineering (ISPE) and a past
Chairman of the Pharmaceutical 3-A Standards Steering Committee
(www.3-a.org), which develops standard for pharmaceutical manufacturing
fabricators and end-users.
